Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306

被引：0
|
作者：
Pietrantonio, F. [1 ]
Garassino, M. C. [1 ]
Torri, V. [2 ]
de Braud, F. [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Med Oncol Unit 1, Milan, Italy
[2] Ist Ric Farmacol Mario Negri, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷 / 10期
关键词：
FLUOROURACIL; LEUCOVORIN; SURVIVAL;
D O I：
10.1093/annonc/mds332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2771 / 2772
页数：2
相关论文
共 50 条
  • [1] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
    Stintzing, S.
    von Weikersthal, L. Fischer
    Decker, T.
    Vehling-Kaiser, U.
    Jaeger, E.
    Heintges, T.
    Stoll, C.
    Giessen, C.
    Modest, D. P.
    Neumann, J.
    Jung, A.
    Kirchner, T.
    Scheithauer, W.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2012, 23 (07) : 1693 - 1699
  • [2] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306
    Stintzing, S.
    Neumann, J.
    Jung, A.
    von Weikersthal, L. Fischer
    Decker, T.
    Vehling-Kaiser, U.
    Jaeger, E.
    Heintges, T.
    Stoll, C.
    Modest, D. P.
    Kirchner, T.
    Scheithauer, W.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).
    Heinemann, Volker
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmueller, Juergen
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Hielscher, Joerg
    Scholz, Michael
    Mueller, Sebastian
    Schaefer, Britta
    Modest, Dominik Paul
    Jung, Andreas
    Stintzing, Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).
    Heinemann, Volker
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmueller, Juergen
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Hielscher, Joerg
    Scholz, Michael
    Mueller, Sebastian
    Schaefer, Britta
    Modest, Dominik Paul
    Jung, Andreas
    Stintzing, Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [5] Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
    Stintzing, S.
    Miller-Phillips, L.
    Modest, D. P.
    von Weikersthal, L. Fischer
    Decker, T.
    Kiani, A.
    Vehling-Kaiser, U.
    Al-Batran, S-E.
    Heintges, T.
    Kahl, C.
    Seipelt, G.
    Kullmann, F.
    Stauch, M.
    Scheithauer, W.
    Held, S.
    Moehler, M.
    Jagenburg, A.
    Kirchner, T.
    Jung, A.
    Heinemann, V.
    EUROPEAN JOURNAL OF CANCER, 2017, 79 : 50 - 60
  • [6] Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: The FIRE-3 trial (AIO KRK 0307)
    Heinemann, V
    von Weikersthal, Fischer L.
    Decker, T.
    Kiani, A.
    Verhling-Kaiser, U.
    Al Batran, S.
    Heintges, T.
    Lerchenmueller, C.
    Kahl, C.
    Seipelt, G.
    Kullmann, F.
    Stauch, M.
    Scheithauer, W.
    Hielscher, J.
    Scholz, M.
    Mueller, S.
    Schaefer, B.
    Moehler, M.
    Modest, D. P.
    Jung, A.
    Stintzing, S.
    ONKOLOGIE, 2013, 36 : 104 - 104
  • [7] Cost-effectiveness of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study
    Stintzing, Sebastian
    van Oostrum, Ilse
    Pescott, Chris P.
    Ronga, Philippe
    Heeg, Bart
    Heinemann, Volker
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (05) : 448 - 455
  • [8] Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
    Stintzing, S.
    Wirapati, P.
    Lenz, H. J.
    Neureiter, D.
    von Weikersthal, L. Fischer
    Decker, T.
    Kiani, A.
    Kaiser, F.
    Al-Batran, S.
    Heintges, T.
    Lerchenmueller, C.
    Kahl, C.
    Seipelt, G.
    Kullmann, F.
    Moehler, M.
    Scheithauer, W.
    Held, S.
    Modest, D. P.
    Jung, A.
    Kirchner, T.
    Aderka, D.
    Tejpar, S.
    Heinemann, V
    ANNALS OF ONCOLOGY, 2019, 30 (11) : 1796 - 1803
  • [9] Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Stintzing, Sebastian
    Wirapati, Pratyaksha
    Lenz, Heinz -Josef
    Neureiter, Daniel
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Kahl, Christoph
    Kullmann, Frank
    Moehler, Markus H.
    Scheithauer, Werner
    Held, Swantje
    Modest, Dominik Paul
    Jung, Andreas
    Kirchner, Thomas
    Tejpar, Sabine
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Cost-effectiveness of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in the first-line treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study.
    Stintzing, Sebastian
    van Oostrum, Ilse
    Pescott, Chris
    Steinbach-Buechert, Alma Katharina
    Heeg, Bart
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345